Refine
Year of publication
Document Type
- Preprint (763)
- Article (625)
- Conference Proceeding (4)
- Doctoral Thesis (1)
- Working Paper (1)
Language
- English (1387)
- German (6)
- Multiple languages (1)
Has Fulltext
- yes (1394)
Is part of the Bibliography
- no (1394)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- BESIII (9)
- LHC (9)
- Branching fraction (7)
- e +-e − Experiments (7)
- Heavy-ion collision (6)
- HIV (5)
- Particle and Resonance Production (5)
- ALICE experiment (4)
- Charm physics (4)
- Collective Flow (4)
- Electroweak interaction (4)
- Inverse kinematics (4)
- Jets (4)
- Lepton colliders (4)
- Quark-Gluon Plasma (4)
- Quasi-free scattering (4)
- ALICE (3)
- Biomarkers (3)
- COVID-19 (3)
- Charm Physics (3)
- Charmed mesons (3)
- Experimental nuclear physics (3)
- Experimental particle physics (3)
- Hadronic decays (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- Oncology (3)
- Osteoporosis (3)
- Particle and resonance production (3)
- QCD (3)
- Quarkonium (3)
- Spectroscopic factors (3)
- breast cancer (3)
- e+-e− Experiments (3)
- pp collisions (3)
- Antiretroviral therapy (2)
- Beauty production (2)
- Bone density (2)
- Branching fractions (2)
- CT (2)
- Cirrhosis (2)
- Diagnostic markers (2)
- Diagnostik (2)
- Electroweak Interaction (2)
- Epilepsy (2)
- Exotics (2)
- Früherkennung (2)
- Heart failure (2)
- Heavy Quark Production (2)
- Hypertension (2)
- Inflammation (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Leptonic, semileptonic & radiative decays (2)
- Liver diseases (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Nuclear reactions (2)
- Particle Correlations and Fluctuations (2)
- Particle correlations and fluctuations (2)
- Particle decays (2)
- Pb–Pb collisions (2)
- Relativistic heavy-ion collisions (2)
- Richtlinie (2)
- Seizure (2)
- Shell model (2)
- Single electrons (2)
- Single-particle states (2)
- Spectroscopy (2)
- Spine (2)
- biomarker (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- pelvic packing (2)
- reference values (2)
- screening (2)
- 900 GeV (1)
- ABC transporters (1)
- ALICE detector (1)
- ALK (1)
- APRI (1)
- ATPases (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Acute coronary syndrome (1)
- Alpha-synuclein (1)
- Angiography (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Antiviral therapy (1)
- Aortic valve (1)
- Apoptosis (1)
- Artesunate (1)
- Atherosclerosis (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- Atrial fibrillation (1)
- B cell receptor (1)
- B cell subpopulations (1)
- BESIII detector (1)
- BRCA1 (1)
- BRCA2 (1)
- Bacterial genomics (1)
- Bayesian inference (1)
- Beam loss (1)
- Bhabha (1)
- Biomarker (1)
- Bipolar disorder (1)
- Bleeding (1)
- Blood plasma (1)
- Blood pressure (1)
- Body mass index (1)
- Bone diseases, Metabolic (1)
- Boosted Jets (1)
- Born cross section measurement (1)
- Breast cancer (1)
- C-clamp (1)
- C3M (1)
- C4M (1)
- CD16 (1)
- CD56 (1)
- COVID 19 (1)
- CP violation (1)
- CRPC (1)
- CT dual-energy computed tomography (1)
- CVID (1)
- Cancer (1)
- Cancer treatment (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardiac troponin (1)
- Cardiology (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell-to-Cell Spread (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Charmonium (1)
- Charmonium (-like) (1)
- Chemoradiotherapy (1)
- Child (1)
- Children (1)
- Chronic obstructive pulmonary disease (1)
- Circular accelerators (1)
- Clinical study (1)
- Clinical variation (1)
- Cohort studies (1)
- Collective Flow, (1)
- Comparative effectiveness research (1)
- Comparison with QCD (1)
- Complex II (1)
- Computed tomography, X-ray (1)
- Consensus (1)
- Consensus document (1)
- Contrast agent (1)
- Costs (1)
- Cross section (1)
- Cross sections (1)
- Culture positive (1)
- D meson (1)
- Dark photon (1)
- Dark sector (1)
- De-isolation (1)
- Death rates (1)
- Dermatomyositis (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Digestive system procedures (1)
- Direct nuclear reactions (1)
- Direct reactions (1)
- Docetaxel (1)
- Drug screens (1)
- Dual-energy computed tomography (1)
- Economics (1)
- Eicosanoids (1)
- Ejection fraction (1)
- Elderly (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Elliptic flow (1)
- Endocrinology (1)
- Endoscopy (1)
- Ephrin-B2–EphB4 (1)
- Esophagectomy (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- Exercise training (1)
- Exosomes (1)
- FAPI PET (1)
- FIB-4 (1)
- FOS: Physical sciences (1)
- Falciparum (1)
- Fatty acids (1)
- Fatty liver (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- First-line combination antiretroviral therapy (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- Forschung (1)
- Frailty (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- General practitioners (1)
- Genetics (1)
- German PID-NET registry (1)
- Gleason Grade Group (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HER2-positive (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Health economics (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion storage ring (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hematology (1)
- Hepatitis B virus (1)
- Hepatitis C virus (1)
- Hepatocellular carcinoma (1)
- Hepatotoxicity (1)
- Hereditary breast and ovarian cancer (1)
- Herniated disk (1)
- High Energy Physics - Experiment (hep-ex) (1)
- High-energy neutron detection (1)
- Human behaviour (1)
- Hyperons (1)
- INR (1)
- IgG substitution therapy (1)
- Image processing (1)
- Implantable cardioverter-defibrillator (1)
- In-TIPS thrombosis (1)
- Inclusive spectra (1)
- Initial state radiation (1)
- Intensity interferometry (1)
- International normalized ratio (1)
- Intervertebral disc displacement (1)
- Invariant Mass Distribution (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- Isoscalar giant resonances (1)
- Jet Physics (1)
- Jet Substructure (1)
- Kidney diseases (1)
- Lehre (1)
- Leukemias (1)
- Liver (1)
- Liver enzymes (1)
- Liver fibrosis (1)
- Liver transplantation (1)
- Long non-coding RNAs (1)
- Low & intermediate-energy accelerators (1)
- MHC (1)
- MRI (1)
- MTOR inhibitor (1)
- MYCN amplification (1)
- Malaria (1)
- Masquelet technique (1)
- Material budget (1)
- MicroRNAs (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Mitochondria (1)
- Molecular diagnostic testing (1)
- Molecular neuroscience (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-neutron detection (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multivariate analysis (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myocardial infarction (1)
- NK cells (1)
- NMR spectroscopy (1)
- Nanoscale biophysics (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant therapy (1)
- Neural network (1)
- Neutrinos (1)
- Non-small cell lung cancer (1)
- Noninferiority (1)
- Nontuberculous mycobacteria (1)
- Nuclear astrophysics (1)
- Nuclear modification factor (1)
- Nuclear physics of explosive environments (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- Oesophagogastric cancer oxaliplatin (1)
- Oldest-old (1)
- One-nucleon removal (1)
- Open pulmonary tuberculosis (1)
- Opportunistic infections (1)
- Optical tweezers (1)
- Orbital electron capture (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Oxidative phosphorylation (1)
- PDE‐5‐inhibitor (1)
- PID prevalence (1)
- PYTHIA (1)
- Pacemaker (1)
- Parkinson’s disease (1)
- Particle phenomena (1)
- Pathological complete response (1)
- Pb–Pb (1)
- Percutaneous (1)
- Personalized medicine (1)
- Phantoms (imaging) (1)
- Phospholipids (1)
- Photon counting (1)
- Physical activity (1)
- Plasmodium (1)
- Plastic scintillator array (1)
- Point-of-care testing (1)
- Polarization (1)
- Pre-treatment drug resistance mutations (1)
- Predictive markers (1)
- Prevention (1)
- Production Cross Section (1)
- Prognosis (1)
- Properties of Hadrons (1)
- Protease inhibitor therapy (1)
- Proton (1)
- Proton–proton (1)
- Psychiatric disorders (1)
- QGP (1)
- Quantitative Imaging (1)
- Quantum chromodynamics (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quinine (1)
- RAS pathway (1)
- Radiative capture (1)
- Radiative decay (1)
- Rapidity Range (1)
- Rare decays (1)
- Reactions with relativistic radioactive beams (1)
- Registries (1)
- Regulatory networks (1)
- Relativistic heavy ion physics (1)
- Renal lesions (1)
- Research (1)
- Residency (1)
- Resolution Parameter (1)
- Respiratory infections (1)
- Retinal diseases (1)
- Rhabdomyoma (1)
- SARS CoV 2 (1)
- SARS-CoV-2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SR-BI (1)
- SVR (1)
- Semi-leptonic decays (1)
- Severe malaria (1)
- Single muons (1)
- Single particle decay spectroscopy (1)
- Sociodemographic characteristics (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Sphingolipids (1)
- Sputum smear-negative (1)
- Stentoplasty (1)
- Storage ring (1)
- Subependymal giant cell astrocytoma (1)
- Super-resolution microscopy (1)
- Surgical oncology (1)
- Systematic Uncertainty (1)
- TB-therapy (1)
- TIPS (1)
- TR (1)
- TSC (1)
- Teaching (1)
- Techniques Electromagnetic calorimeters (1)
- Time Projection Chamber (1)
- Tomography (1)
- Tomography (x-ray computed) (1)
- Tracking (1)
- Transferases (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transjugular Intrahepatic Portosystemic Shunt (1)
- Transverse momentum (1)
- Trigger (1)
- Triple negative (1)
- Triple-negative breast cancer (1)
- Two body weak decay (1)
- Type 2 diabetes (1)
- University hospitals (1)
- Universitätskliniken (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Viral load (1)
- Virological failure (1)
- Virtual noncalcium reconstructions (1)
- Weiterbildung (1)
- X-ray computed (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Y states (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- acute myeloid leukemia (1)
- adaptive immunity (1)
- adult and elderly patients (1)
- allogeneic transplantation (1)
- angiography (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- annual bleeding rate (1)
- anterior chamber depth changes (1)
- antigen presentation (1)
- auditory system (1)
- autoimmunity (1)
- biopsy cores (1)
- bone marrow derived mononuclear cells (1)
- cART (1)
- cancer therapy (1)
- cardiac magnetic resonance (1)
- castration resistance (1)
- cataract surgery (1)
- cell-free protein synthesis (1)
- center-of-mass energy (1)
- charmonium-like states (1)
- children (1)
- chronic kidney disease (1)
- clinical stage (1)
- co-infection (1)
- cohlear implant (1)
- cohort study (1)
- collagen degradation marker (1)
- component study (1)
- computer-assisted (1)
- critical size defect (1)
- cryo-EM (1)
- cyanines (1)
- cytarabine dose (1)
- dE/dx (1)
- decision aids (1)
- detector (1)
- dimuon (1)
- dislocation (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- e-scooter (1)
- effective lens position (1)
- effectiveness (1)
- elderly (1)
- electric and acustic stymulation (1)
- electric scooter (1)
- electron-positron collision (1)
- embolization (1)
- erectile dysfunction (1)
- experimental results (1)
- exponential model (1)
- external fixation (1)
- fibrosis imaging (1)
- fibrotest (1)
- flow cytometry (1)
- fracture (1)
- hadron spectroscopy (1)
- hadronic events (1)
- haemophilia A (1)
- head-and-neck cancer (1)
- heavy ion experiments (1)
- heavy-ion storage rings (1)
- helicity amplitude analysis (1)
- hemodynamic instability (1)
- hemorrhage (1)
- hepatitis C (1)
- high-risk neuroblastoma (1)
- immune reconstitution (1)
- inclusive J/ψ decays (1)
- induced membrane (1)
- interoperability (1)
- intrinsically disordered region (1)
- inverse kinematics (1)
- lactate (1)
- lapatinib (1)
- learning loss (1)
- lung cancer (1)
- mTOR inhibitor (1)
- management (1)
- membrane proteins (1)
- metastasis (1)
- metastatic prostate cancer (1)
- mindfulness (1)
- molecular machines (1)
- molecular tug-of-war (1)
- mortality (1)
- myocardial fibrosis (1)
- neoadjuvant therapy (1)
- neutron-induced reactions (1)
- non-ST-segment elevation acute coronary syndrome (1)
- non-invasive fibrosis assessment (1)
- nonstructural proteins (1)
- non‐selective beta‐blocker (1)
- nuclear cardiology (1)
- number of J/ψ events (1)
- oxLDL (1)
- p53 pathway (1)
- pelvic injury (1)
- pelvic ring fracture (1)
- peptide editing (1)
- peptide-loading complex (1)
- photoacid (1)
- phylogeny (1)
- plasma-derived factor VIII concentrate, prophylaxis (1)
- point shear wave elastography (1)
- portal hypertension (1)
- primary active transporters (1)
- primary immunodeficiency (PID) (1)
- proteomics (1)
- proton transfer (1)
- pseudoexfoliative syndrome (1)
- psychotherapy process (1)
- quality control (1)
- quark gluon plasma (1)
- randomized controlled trial (RCT) (1)
- registry for primary immunodeficiency (1)
- resectability (1)
- risk group (1)
- scaffold size (1)
- scar (1)
- school closure (1)
- seed and soil (1)
- sequence alignment (1)
- smart home (1)
- smart living (1)
- spectra (1)
- sphingolipid (1)
- spinal bone metastasis (1)
- spine (1)
- spiro compounds (1)
- stage migration (1)
- structural biology (1)
- structural proteins (1)
- student achievement (1)
- surrogate reactions (1)
- survival (1)
- systematic review (1)
- tapasin (1)
- tetraquark (1)
- therapeutic alliance (1)
- traffic accident (1)
- transient elastography (1)
- transportation (1)
- trastuzumab (1)
- traumatic brain injury (1)
- trigger efficiency (1)
- ultrafast spectroscopy (1)
- vertebroplasty (1)
- web of things (1)
- x-ray techniques (1)
- Λ+c baryon (1)
- Σ hyperon (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1261)
- Frankfurt Institute for Advanced Studies (FIAS) (956)
- Informatik (921)
- Medizin (103)
- ELEMENTS (18)
- Geowissenschaften (10)
- Biochemie und Chemie (5)
- Exzellenzcluster Herz-Lungen-System (3)
- Informatik und Mathematik (3)
- Biochemie, Chemie und Pharmazie (2)
The neutron activation method is well-suited to investigate neutron-capture cross sections relevant for the main s-process component. Neutrons can be produced via the 7Li(p,n) reaction with proton energies of 1912 keV at e.g. Van de Graaff accelerators, which results in a quasi-Maxwellian spectrum of neutrons corresponding to a temperature of kBT = 25 keV. However, the weak s-process takes place in massive stars at temperatures between 25 and 90 keV. Simulations using the PINO code [2] suggest that a Maxwellian spectrum for higher energies, e.g. kBT = 90 keV, can be approximated by a linear combination of different neutron spectra. To validate the PINO code at proton energies Ep ≠ 1912 keV, neutron time-of-flight measurements were carried out at the PTB Ion Accelerator Facility (PIAF) at the Physikalisch-Technische Bundesanstalt in Braunschweig, Germany.
The highly infectious disease COVID-19 caused by the Betacoronavirus SARS-CoV-2 poses a severe threat to humanity and demands the redirection of scientific efforts and criteria to organized research projects. The international COVID19-NMR consortium seeks to provide such new approaches by gathering scientific expertise worldwide. In particular, making available viral proteins and RNAs will pave the way to understanding the SARS-CoV-2 molecular components in detail. The research in COVID19-NMR and the resources provided through the consortium are fully disclosed to accelerate access and exploitation. NMR investigations of the viral molecular components are designated to provide the essential basis for further work, including macromolecular interaction studies and high-throughput drug screening. Here, we present the extensive catalog of a holistic SARS-CoV-2 protein preparation approach based on the consortium’s collective efforts. We provide protocols for the large-scale production of more than 80% of all SARS-CoV-2 proteins or essential parts of them. Several of the proteins were produced in more than one laboratory, demonstrating the high interoperability between NMR groups worldwide. For the majority of proteins, we can produce isotope-labeled samples of HSQC-grade. Together with several NMR chemical shift assignments made publicly available on covid19-nmr.com, we here provide highly valuable resources for the production of SARS-CoV-2 proteins in isotope-labeled form.
Members of the ATP‐binding cassette (ABC) transporter superfamily translocate a broad spectrum of chemically diverse substrates. While their eponymous ATP‐binding cassette in the nucleotide‐binding domains (NBDs) is highly conserved, their transmembrane domains (TMDs) forming the translocation pathway exhibit distinct folds and topologies, suggesting that during evolution the ancient motor domains were combined with different transmembrane mechanical systems to orchestrate a variety of cellular processes. In recent years, it has become increasingly evident that the distinct TMD folds are best suited to categorize the multitude of ABC transporters. We therefore propose a new ABC transporter classification that is based on structural homology in the TMDs:
Since the introduction of rental E-scooters in Germany in mid-June 2019, the safety of this new means of transport has been the subject of extensive public debate. However, valid data on injuries and usage habits are not yet available. This retrospective two-center study included a total of 76 patients who presented to the emergency department following E-scooter-related accidents. The mean age was 34.3 ± 12.4 years and 69.7% of the patients were male. About half of the patients were admitted by ambulance (42.1%). Fractures were found in 48.6% of patients, and 27.6% required surgical treatment due to a fracture. The upper extremities were the most commonly affected body region, followed by injuries to the lower extremity and to the head and face. Only one patient had worn a helmet. In-hospital treatment was necessary for 26.3% of the cases. Patients presented to the emergency department mainly during the weekend and on-call times. This is the first report on E-scooter-related injuries in Germany. Accidents with E-scooters can cause serious injuries and, therefore, represent a further burden to emergency departments. The use of E-scooters appears to be mostly recreational, and the rate of use of protective gear is low.
Background: A trend towards inverse stage migration in prostate cancer (PCa) was reported. However, previous analyses did not take into account potential differences in sampling strategies (number of biopsy cores), which might have confounded these reports.
Material and Methods: Within our single-institutional database we identified PCa patients treated with radical prostatectomy (RP) between 2000 and 2020 (n = 21,646). We calculated the estimated annual percentage change (EAPC) for D'Amico risk groups, biopsy Gleason Grade Group (GGG), PSA and cT stage as well as postoperative RP GGG and pT stage relying on log linear regression methodology. Subsequently, we repeated the analyses after adjustment for number of cores obtained at biopsy.
Results: Absolute rates of D'Amico low risk decreased (−30.1%), while intermediate and high risk increased (+21.2% and +9.0%, respectively). Rates of GGG I decreased (−50.0%), while GGG II–V increased, with the largest increase in GGG II (+22.5%). This trend, albeit less pronounced, was also recorded after adjusted EAPC analyses (p < .05). Specifically, EAPC values for D'Amico low vs intermediate vs high risk were −1.07%, +0.37%, +0.45%, respectively, and EAPC values for GGG ranged between −0.71% (GGG I) and +0.80% (GGG IV). Finally, an increase in ≥cT2 (EAPC: +3.16%) was displayed (all p < .001). These trends were confirmed in EAPC calculations in RP GGG and pT stages (p < .001).
Conclusion: Our findings confirm the trend towards less frequent treatment of low risk PCa and more frequent treatment of high risk PCa, also after adjustment for number of biopsy cores.
Background: To evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) in the era of combination therapies for mHSPC.
Material and Methods: Of 213 mHSPC patients diagnosed between 01/2013-12/2020 who subsequently developed metastatic castration resistant prostate cancer (mCRPC), 204 eligible patients were analyzed after having applied exclusion criteria. mHSPC patients were classified into TTCR <12, 12-18, 18-24, and >24 months and analyzed regarding OS. Moreover, further OS analyses were performed after having developed mCRPC status according to TTCR. Logistic regression models predicted the value of TTCR on OS.
Results: Median follow-up was 34 months. Among 204 mHSPC patients, 41.2% harbored TTCR <12 months, 18.1% for 12-18 months, 15.2% for 18-24 months, and 25.5% for >24 months. Median age was 67 years and median PSA at prostate cancer diagnosis was 61 ng/ml. No differences in patient characteristics were observed (all p>0.05). According to OS, TTCR <12 months patients had the worst OS, followed by TTCR 12-18 months, 18-24 months, and >24 months, in that order (p<0.001). After multivariable adjustment, a 4.07-, 3.31-, and 6.40-fold higher mortality was observed for TTCR 18-24 months, 12-18 months, and <12 months patients, relative to TTCR >24 months (all p<0.05). Conversely, OS after development of mCRPC was not influenced by TTCR stratification (all p>0.05).
Conclusion: Patients with TTCR <12 months are at the highest OS disadvantage in mHSPC. This OS disadvantage persisted even after multivariable adjustment. Interestingly, TTCR stratified analyses did not influence OS in mCRPC patients.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feasibility and safety of azacitidine combined with a cytarabine- and daunorubicin-based chemotherapy in older patients with AML.
TRIAL DESIGN: Prospective, randomised, open, phase II trial with parallel group design and fixed sample size.
PATIENTS AND METHODS: Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of <20,000/µl at the time of study entry and adequate organ function were eligible. Patients were randomised to receive azacitidine either 37.5 (dose level 1) or 75 mg/sqm (dose level 2) for five days before each cycle of induction (7+3 cytarabine plus daunorubicine) and consolidation (intermediate-dose cytarabine) therapy. Dose-limiting toxicity was the primary endpoint.
RESULTS: Six patients each were randomised into each dose level and evaluable for analysis. No dose-limiting toxicity occurred in either dose level. Nine serious adverse events occurred in five patients (three in the 37.5 mg, two in the 75 mg arm) with two fatal outcomes. Two patients at the 37.5 mg/sqm dose level and four patients at the 75 mg/sqm level achieved a complete remission after induction therapy. Median overall survival was 266 days and median event-free survival 215 days after a median follow up of 616 days.
CONCLUSIONS: The combination of azacitidine 75 mg/sqm with standard induction therapy is feasible in older patients with AML and was selected as an investigational arm in the randomised controlled part of this phase-II study, which is currently halted due to an increased cardiac toxicity observed in the experimental arm.
The transverse mass mt distributions for deuterons and protons are measured in Pb+Pb reactions near midrapidity and in the range 0<mt–m<1.0 (1.5) GeV/c2 for minimum bias collisions at 158A GeV and for central collisions at 40 and 80 A GeV beam energies. The rapidity density dn/dy, inverse slope parameter T and mean transverse mass <mt> derived from mt distributions as well as the coalescence parameter B2 are studied as a function of the incident energy and the collision centrality. The deuteron mt spectra are significantly harder than those of protons, especially in central collisions. The coalescence factor B2 shows three systematic trends. First, it decreases strongly with increasing centrality reflecting an enlargement of the deuteron coalescence volume in central Pb+Pb collisions. Second, it increases with mt. Finally, B2 shows an increase with decreasing incident beam energy even within the SPS energy range. The results are discussed and compared to the predictions of models that include the collective expansion of the source created in Pb+Pb collisions.
Background: Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.
Methods: HIV-infected children <18 years initiating cART between 1998 and 2008 were included if having at least one genotypic resistance test prior to cART initiation. We used the World Health Organization 2009 resistance mutation list and Stanford algorithm to infer resistance to prescribed drugs. Time to virological failure (VF) was defined as the first of two consecutive HIV-RNA > 500 copies/mL after 6 months cART and was assessed by Cox proportional hazards models. All models were adjusted for baseline demographic, clinical, immunology and virology characteristics and calendar period of cART start and initial cART regimen.
Results: Of 476 children, 88 % were vertically infected. At cART initiation, median (interquartile range) age was 6.6 years (2.1–10.1), CD4 cell count 297 cells/mm3 (98–639), and HIV-RNA 5.2 log10copies/mL (4.7–5.7). Of 37 children (7.8 %, 95 % confidence interval (CI), 5.5–10.6) harboring a virus with ≥1 PDR mutations, 30 children had a virus resistant to ≥1 of the prescribed drugs. Overall, the cumulative Kaplan-Meier estimate for virological failure was 19.8 % (95 %CI, 16.4–23.9). Cumulative risk for VF tended to be higher among children harboring a virus with PDR and resistant to ≥1 drug prescribed than among those receiving fully active cART: 32.1 % (17.2–54.8) versus 19.4 % (15.9–23.6) (P = 0.095). In multivariable analysis, age was associated with a higher risk of VF with a 12 % reduced risk per additional year (HR 0.88; 95 %CI, 0.82–0.95; P < 0.001).
Conclusions: PDR was not significantly associated with a higher risk of VF in children in the first year of cART. The risk of VF decreased by 12 % per additional year at treatment initiation which may be due to fading of PDR mutations over time. Lack of appropriate formulations, in particular for the younger age group, may be an important determinant of virological failure.